Michael Burry, the legendary “Big Short” investor and founder of Scion Asset Management has revealed a substantial reshuffle in his Q2 2025 holdings, adding heavyweight names across healthcare, retail, biotech, and e-commerce while trimming his largest position.
According to his latest 13F filing, Burry initiated new positions in UnitedHealth Group Inc. (NYSE: UNH), Lululemon Athletica Inc. (NASDAQ: LULU), Bruker Corp. (NASDAQ: BRKR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), and MercadoLibre Inc. (NASDAQ: MELI).
At the same time, he reduced his stake in Estee Lauder Cos. Inc. (NYSE: EL) by 25%, though it remains his single largest holding, accounting for 21.55% of the portfolio.
Burry’s UNH stock portfolio
UnitedHealth’s addition is particularly notable. Burry purchased 20,000 shares at $311.95 each, a position now valued at $271.49, representing a 12.97% decline.
The move puts him in the same camp as other institutional heavyweights including Warren Buffett, David Tepper, and Saudi sovereign wealth funds, all of which boosted their UnitedHealth stakes in Q2.
Institutional interest in the healthcare giant is also surging, with analysts forecasting considerable upside potential into 2026 and beyond.
Elsewhere, Lululemon was acquired at $237.58 per share, but the stock now trades at $195.19, down 17.84% since the purchase. Bruker was bought at $41.20 and has since slipped 18.35% to $33.64. MercadoLibre entered the portfolio at $2,613.67 and now sits at $2,319.80, marking an 11.24% decline. Regeneron, however, has been a bright spot, climbing 7.80% from Burry’s $525 entry price to $565.97.
While several of these new positions are currently trading below Burry’s purchase price, the investor’s track record shows a willingness to weather short-term volatility in pursuit of outsized long-term gains.
At the time of publication, UnitedHealth trades at $305.90, still far below its 52-week high of $621.24, suggesting that Burry may view the current weakness as an opportunity.
